TatyanaSimuniMD

Neurology • Chicago, IL

Neurophysiology

Physician

Join to view full profile

Dr. Simuni is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Simuni's full profile

Already have an account?

Office
259 E Erie St
Chicago, IL 60611
Phone+1 312-503-1944

Education & Training

Temple University HospitalResidency, Neurology, 1991 - 1995
Albert Einstein Healthcare NetworkInternship, Internal Medicine, 1990 - 1991
St Petersburg State Pediatric Medicine AcademyClass of 1985

Certifications & Licensure

IL State Medical License 1996 - 2026
PA State Medical License 1993 - 2002
NJ State Medical License 1995 - 2001
American Board of Psychiatry and Neurology Neurology

Publications & Presentations

PubMed

Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study.
Aaron L Ellenbogen, Werner Poewe, Alberto J Espay, Tanya Simuni, Tanya Gurevich
Parkinsonism & Related Disorders. 2025-03-01
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's ...
Tania Nikolcheva, Gennaro Pagano, Nathalie Pross, Tanya Simuni, Kenneth Marek
Parkinsonism & Related Disorders. 2025-03-01
An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.
Niraj M Shanbhag, Jaya L Padmanabhan, Zheng Zhang, Brian T Harel, Hongxia Jia
JAMA Neurology. 2025-02-01

Press Mentions

Staging System Predicts Early-Stage Parkinson’s Time to ProgressionDecember 5th, 2024
Improving Diagnosis and Tracking of Neurodegenerative DiseasesNovember 22nd, 2024
Investigational Med for Tourette Syndrome PromisingOctober 1st, 2024
Join now to see all